Management ChangeAug 10, 2026, 04:09 PM
Agomab Proposes Marino Garcia, Naimish Patel to Board
AI Summary
Agomab Therapeutics NV announced the proposed appointments of Marino Garcia and Naimish Patel, M.D. to its Board of Directors. These appointments, aimed at strengthening the Board with extensive biotech and clinical development expertise, will be put to a shareholder vote at a Special General Meeting on September 11, 2026. Concurrently, the company will hold an Extraordinary General Shareholders' Meeting to seek approval for the consolidation and split of outstanding pre-IPO warrants, adjusting them to reflect the share split implemented during its February 2026 IPO.
Key Highlights
- Agomab proposes Marino Garcia and Naimish Patel, M.D. as non-executive Board members.
- Appointments to be submitted for shareholder approval at a Special General Meeting on September 11, 2026.
- Marino Garcia is CEO of Dianthus Therapeutics, bringing experience in biotech growth and financing.
- Naimish Patel, M.D. is CMO of CRISPR Therapeutics, with expertise in clinical development and immunology.
- Company will also hold an Extraordinary General Shareholders' Meeting for pre-IPO warrant consolidation and split.
- Pre-IPO warrants to be adjusted to reflect the share split from Agomab's February 2026 IPO.
Price Impact
More from AGMB